Home Biosimilar Antibodies Transmembrane Transporters CD markers -LAG-3 Relatlimab (anti-LAG-3)
For research use only. Not for use in humans.

Relatlimab (anti-LAG-3)

Synonyms: CD223， LAG3

Relatlimab (BMS-986016, RELA) is a human LAG-3 specific monoclonal antibody that binds to LAG-3 on T cells, restoring effector function of exhausted T cells.

Relatlimab (anti-LAG-3)

Click to purchase the isotype control of Relatlimab (anti-LAG-3)

3 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: A202905 Purity: 99% Protein concentration: 5.3 mg/ml Endotoxin Level: <1 EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Relatlimab (BMS-986016, RELA) is a human LAG-3 specific monoclonal antibody that binds to LAG-3 on T cells, restoring effector function of exhausted T cells.
References

Product Details

CAS No. 1673516-98-7
Molecular Weight 145.3 kDa
Isotype Human IgG4, κ
Source CHO Cells
Purification Protein G
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07369791 WITHDRAWN Drug: Nivolumab|Drug: Gemcitabine|Drug: Cisplatin|Drug: Nivo Advanced Biliary Tract Cancer(BTC) National Health Research Institutes, Taiwan 2026-12 PHASE2
NCT07644312 NOT_YET_RECRUITING Drug: Opdualag High Grade Glioma; Diffuse Intrinsic Pontine Glioma; WHO Grade 3 Glioma; WHO Grade 4 Glioma; Replication Repair Deficient Nationwide Children's Hospital 2027-03-01 PHASE2
NCT07567469 NOT_YET_RECRUITING Drug: Cemiplimab|Drug: Cemiplimab+Fianlimab Fixed Dose Combi High-Grade Glioma (HGG); Posterior Fossa-A Ependymoma Regeneron Pharmaceuticals 2026-08-31 PHASE1; PHASE2
NCT06715241 ACTIVE_NOT_RECRUITING LOCALLY ADVANCED CERVICAL CANCERS ARCAGY/ GINECO GROUP 2024-12-11 PHASE2
NCT07281924 RECRUITING Drug: Nivolumab and Relatlimab Metastatic Melanoma; Liver Metastases University of Wisconsin, Madison 2026-09 PHASE1; PHASE2
NCT06963905 RECRUITING Drug: Relatlimab FDC + Nivolumab|Drug: Sacituzumab Govitecan Metastatic Triple-negative Breast Cancer Yale University 2025-12-29 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-07-02)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.